Free Trial
OTCMKTS:SIGY

Sigyn Therapeutics Q4 2024 Earnings Results & Report

Sigyn Therapeutics logo
$0.03 -0.01 (-16.67%)
As of 03:59 PM Eastern

Sigyn Therapeutics reported Q4 2024 earnings on April 15, 2025. The company reported EPS of -$2.51.

Earnings Announcement Details

Quarter
Q4 2024
Report Date

Sigyn Therapeutics EPS Results

Actual EPS
-$2.51
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sigyn Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Sigyn Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026, based on past reporting schedules.

Conference Call Resources

Sigyn Therapeutics Q4 2024 Earnings FAQ

Sigyn Therapeutics (OTCMKTS:SIGY) reported earnings of -$2.51 per share for Q4 2024. The report was announced on Tuesday, April 15, 2025.

Sigyn Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Sigyn Therapeutics on the company's earnings history page.

Sigyn Therapeutics Earnings Headlines

SIGY Sigyn Therapeutics Inc.
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
Sigyn Therapeutics Delays Annual SEC Filing
See More Sigyn Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sigyn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sigyn Therapeutics and other key companies, straight to your email.

About Sigyn Therapeutics

Sigyn Therapeutics (OTCMKTS:SIGY) is a biotechnology company focused on developing therapeutic technologies intended to address systemic inflammation and infectious diseases. Its primary product candidate, Sigyn Therapy, is designed to remove pro-inflammatory cytokines and pathogen-associated materials from circulating blood, with potential applications in conditions such as cancer and severe infections.

Sigyn Therapy is an investigational blood-purification technology and has not been established as a commercially approved treatment. The company’s development activities center on evaluating the platform’s ability to modulate immune-system responses and support patients whose diseases or treatments may produce harmful inflammatory reactions.

Sigyn Therapeutics is headquartered in the United States and serves the biopharmaceutical and medical-device markets through research and development of its proprietary technology. Publicly available information about the company’s broader commercial operations, geographic reach and current leadership is limited.

View Sigyn Therapeutics Profile